Effects of WeChat-based telehealth on patients reported outcomes of hypertension: a randomized controlled trial

基于微信的远程医疗对高血压患者报告结局的影响:一项随机对照试验

阅读:1

Abstract

Patient-reported outcomes (PROs) are assessments based on patients' self-perception. This study aimed to explore whether WeChat-based health education is more effective than traditional health education in terms of improving PROs for hypertensive patients during a 3-month period. This prospective, single-center, single-blind randomized controlled trial was conducted from April to August 2022 at the hypertension ward of Yunnan Province Fuwai Cardiovascular Hospital. A total of 96 patients who were aged 18-75 years and diagnosed with primary hypertension for the first time were recruited. The participants were randomly assigned to either the WeChat health education group or the conventional care group at a 1:1 ratio. The intervention lasted for 3 months, with PRO scales administered at baseline (T0), 1 month postintervention (T1), and 3 months postintervention (T2). The experiment ultimately enrolled 96 people, with a mean age of 41 years for the intervention group and 43 years for the control group. Regarding the main outcomes, the total PRO scores of the WeChat group significantly increased from 79.29 points at baseline to 83.68 points after the interventions (95% CI - 7.373, - 1.400; P < 0.05). Additionally, there were significant intergroup differences at 1 month postintervention (TOT: mean difference in change between groups: 3.95, 95% CI 0.127, 7.766, P < 0.05) and at 3 months postintervention (TOT: mean difference in change between groups: 5.05, 95% CI 1.26, 8.833, P < 0.05). This trial demonstrated that WeChat-based telehealth interventions have a positive effect on PROs. The incorporation of digital health education and telehealth interventions can serve as an adjuvant treatment for hypertensive patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。